Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899104 · ClinicalTrials.gov registry record
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
A clinical trial of Prostatic Neoplasms, Castration-Resistant, sponsored by Bayer.
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT02899104 is a study of Prostatic Neoplasms, Castration-Resistant that has completed, run by Bayer. The registered enrollment target is 200 participants, below the 721-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02899104, a study of Prostatic Neoplasms, Castration-Resistant, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
Conditions Studied
Interventions
- DRUG Xofigo (Radium-223 dichloride, BAY88-8223)
Study Locations (1)
New Jersey
- Whippany - Whippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2019-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02899104
The ClinicalTrials.gov registry entry for NCT02899104 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 721-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (72% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 1 intervention - of which Xofigo (Radium-223 dichloride, BAY88-8223) is the first listed.
NCT02899104 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02899104 about?
NCT02899104 is a clinical study titled "Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )". Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
What is the current status of trial NCT02899104?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2017-06-15. Estimated completion is 2019-03-31.
What conditions does trial NCT02899104 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT02899104?
The interventions under investigation include: Xofigo (Radium-223 dichloride, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02899104?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02899104 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms, Castration-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RECRUITING · Phase 1
-
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
-
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 3
-
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.